Income Before Tax
Pre-Tax Income
Alnylam Pharmaceuticals Pre-Tax Income increased by 81.8% to $221.65M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 9460.3%, from -$2.37M to $221.65M. Over 4 years (FY 2021 to FY 2025), Pre-Tax Income shows an upward trend with a -21.5% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementIncome Statement
SectionIncome Before Tax
CategoryProfitability
SignalHigher is better
VolatilityModerate
First reportedQ4 2013
Last reportedQ4 2025
How to read this metric
This provides a view of profitability that is not skewed by varying tax rates or one-time tax credits.
Detailed definition
A company's profits before the deduction of corporate income tax. It combines operating performance with non-operating f...
Peer comparison
Used to compare companies across different tax jurisdictions to see who generates more raw profit.
Metric ID:
income_before_taxHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$188.33M | -$204.24M | -$260.30M | -$239.36M | -$274.67M | -$405.94M | -$207.02M | -$172.36M | -$274.21M | $150.74M | -$137.69M | -$63.59M | -$11.17M | -$108.66M | -$193.96M | -$2.37M | -$35.36M | $238.97M | $121.91M | $221.65M |
| QoQ Change | — | -8.4% | -27.5% | +8.0% | -14.8% | -47.8% | +49.0% | +16.7% | -59.1% | +155.0% | -191.3% | +53.8% | +82.4% | -873.1% | -78.5% | +98.8% | <-999% | +775.9% | -49.0% | +81.8% |
| YoY Change | — | — | — | — | -45.8% | -98.8% | +20.5% | +28.0% | +0.2% | +137.1% | +33.5% | +63.1% | +95.9% | -172.1% | -40.9% | +96.3% | -216.6% | +319.9% | +162.9% | >999% |
Range-$405.94M – $238.97M
CAGR+3.5%
Avg YoY Growth+615.2%
Median YoY Growth+30.7%
Pre-Tax Income at Other Companies
Frequently Asked Questions
- What is Alnylam Pharmaceuticals's pre-tax income?
- Alnylam Pharmaceuticals (ALNY) reported pre-tax income of $221.65M in Q1 2026.
- How has Alnylam Pharmaceuticals's pre-tax income changed year-over-year?
- Alnylam Pharmaceuticals's pre-tax income increased by 9460.3% year-over-year, from -$2.37M to $221.65M.
- What is the long-term trend for Alnylam Pharmaceuticals's pre-tax income?
- Over 4 years (2021 to 2025), Alnylam Pharmaceuticals's pre-tax income has grown at a -21.5% compound annual growth rate (CAGR), from -$852.14M to $323.15M.
- What does pre-tax income mean?
- The total profit a company made before paying its income taxes.